For example, reduction of MED19 by siRNA has been reported to reduce the proliferation of certain breast, ovarian, cervical, and lung cancer cell lines, and increased abundance of MED19 protein is observed in tumors compared to benign tissue [21,57–63]. Here, MED19 is linked to lung carcinoma.